More than a dozen analyst-approved foreign large-cap funds own these names.
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Tucson To Host Globally Recognized Cancer Research Conference Feb. 25 And 26
Brand recognition and product innovation keep the firm's moat wide.
While a majority of our top fund managers are outperforming this year, five of them truly stand out from the rest given their ability to outperform the market over all time periods.
This fund's comeback from the financial crisis has been balky, but it still has promise.
This year's list contains the 1998 and 2008 winners of the award.
You won't see much fireworks here except for maybe a snake or some caps.
The five biotech ETFs have very different portfolios with markedly different performance.
Foreign firms that have established competitive advantages in China are well-positioned to profit from consumption growth.